Aldeyra Therapeutics, Inc. (ALDX) Financial Statements (2023 and earlier)

Company Profile

Business Address 131 HARTWELL AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 29,881,520229,790,98977,858,31144,425,83047,357,47242,946,799
Cash and cash equivalents  229,790,98977,858,31144,425,83047,357,47220,023,337
Short-term investments 29,881,520  28,938,545 22,923,462
Other undisclosed cash, cash equivalents, and short-term investments    (28,938,545)  
Prepaid expense      
Other undisclosed current assets151,141,5932,961,7815,200,95730,742,99547,411,8141,018,967
Total current assets:181,023,113232,752,77083,059,26875,168,82594,769,28643,965,766
Noncurrent Assets
Operating lease, right-of-use asset249,265351,863233,310201,007
Property, plant and equipment19,27932,48759,925148,449235,22543,262
Other undisclosed noncurrent assets     86,644165,930
Total noncurrent assets:268,544384,350293,235349,456321,869209,192
TOTAL ASSETS:181,291,657233,137,12083,352,50375,518,28195,091,15544,174,958
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,199,51011,543,0558,516,40312,681,4248,473,1763,237,428
Accounts payable133,6251,019,702381,638808,3023,051,6781,000,963
Accrued liabilities14,065,88510,523,3538,134,76511,873,1225,421,4982,236,465
Debt911,763 3,659,776226,328 116,319
Other undisclosed current liabilities249,265229,607233,310   
Total current liabilities:15,360,53811,772,66212,409,48912,907,7528,473,1763,353,747
Noncurrent Liabilities
Long-term debt and lease obligation14,923,09015,628,93511,434,45614,528,212 1,220,192
Long-term debt, excluding current maturities14,923,09015,503,70311,434,45614,528,212 1,220,192
Operating lease, liability  125,232  
Other undisclosed noncurrent liabilities  (125,232)    
Total noncurrent liabilities:14,923,09015,628,93511,434,45614,528,212 1,220,192
Total liabilities:30,283,62827,401,59723,843,94527,435,9648,473,1764,573,939
Equity
Equity, attributable to parent151,008,029205,735,52359,508,55848,082,31786,617,97939,601,019
Common stock58,56058,08138,66728,65726,24419,138
Additional paid in capital507,770,045500,369,444296,385,619247,409,793225,136,127139,241,635
Accumulated other comprehensive income (loss) (103,938)  5,866(9,224)(17,831)
Accumulated deficit(356,716,638)(294,692,002)(236,915,728)(199,361,999)(138,535,168)(99,641,923)
Total equity:151,008,029205,735,52359,508,55848,082,31786,617,97939,601,019
TOTAL LIABILITIES AND EQUITY:181,291,657233,137,12083,352,50375,518,28195,091,15544,174,958

Income Statement (P&L) (USD)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(62,679,987)(56,219,536)(34,666,755)(56,506,553)(39,699,151)(22,488,388)
Other undisclosed operating loss   (1,754,265)(6,567,754)  
Operating loss:(62,679,987)(56,219,536)(36,421,020)(63,074,307)(39,699,151)(22,488,388)
Nonoperating income (expense)655,351(1,556,738)(1,611,974)937,503805,906147,799
Investment income, nonoperating2,349,449185,363292,2241,541,349952,698261,252
Interest and debt expense(1,694,098)(1,742,101)(1,904,198)(603,846)(146,792)(113,453)
Loss from continuing operations before equity method investments, income taxes:(63,718,734)(59,518,375)(39,937,192)(62,740,650)(39,040,037)(22,454,042)
Other undisclosed income from continuing operations before income taxes  1,742,1011,904,198603,846  
Loss from continuing operations before income taxes:(63,718,734)(57,776,274)(38,032,994)(62,136,804)(39,040,037)(22,454,042)
Income tax benefit   479,2651,309,973  
Loss from continuing operations:(63,718,734)(57,776,274)(37,553,729)(60,826,831)(39,040,037)(22,454,042)
Loss before gain (loss) on sale of properties:(57,776,274)(37,553,729)(60,826,831)(39,040,037)(22,454,042)
Other undisclosed net income1,694,098     
Net loss:(62,024,636)(57,776,274)(37,553,729)(60,826,831)(39,040,037)(22,454,042)
Other undisclosed net income attributable to parent    146,792113,453
Net loss available to common stockholders, diluted:(62,024,636)(57,776,274)(37,553,729)(60,826,831)(38,893,245)(22,340,589)

Comprehensive Income (USD)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(62,024,636)(57,776,274)(37,553,729)(60,826,831)(39,040,037)(22,454,042)
Other comprehensive income (loss)(103,938) (5,866)15,0908,607(17,960)
Comprehensive loss:(62,128,574)(57,776,274)(37,559,595)(60,811,741)(39,031,430)(22,472,002)
Other undisclosed comprehensive income, net of tax, attributable to parent    146,792113,453
Comprehensive loss, net of tax, attributable to parent:(62,128,574)(57,776,274)(37,559,595)(60,811,741)(38,884,638)(22,358,549)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: